Enzalutamide adds 5 months survival in late-stage prostate cancer
Results of a phase III clinical trial of the drug Enzalutamide, published August 16 in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.read more